New immunotherapy drug tislelizumab targets Hard-to-Treat cancers
NCT ID NCT03736889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing tislelizumab, an immunotherapy drug, in 200 people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR) and have not responded to prior treatments. The drug works by blocking PD-1, helping the immune system recognize and attack cancer cells. The main goal is to see how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (an immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this could offer a new treatment option for people with advanced cancers that have specific genetic features (MSI-H or dMMR) and have not responded to prior therapies.
What could go wrong
This is a mid-stage (Phase 2) trial with no control group, so results are preliminary. The drug may not work for all tumor types, and side effects from immune activation (e.g., inflammation of organs) are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Hebei University
COMPLETEDBaoding, Hebei, 071000, China
-
Affiliated Zhongshan Hospital of Fudan University
COMPLETEDShanghai, Shanghai Municipality, 200032, China
-
Anhui Provincial Hospital
COMPLETEDHefei, Anhui, 230000, China
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Cancer Hospital Chinese Academy of Medical Sciences
COMPLETEDBeijing, Beijing Municipality, 100021, China
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400030, China
-
Fudan University Shanghai Cancer Center
COMPLETEDShanghai, Shanghai Municipality, 200000, China
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
-
Guangdong Provincial Peoples Hospital
COMPLETEDGuangzhou, Guangdong, 510080, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
COMPLETEDZhengzhou, Henan, 450000, China
-
Hubei Cancer Hospital
COMPLETEDWuhan, Hubei, 430079, China
-
Huizhou First Hospital
RECRUITINGHuizhou, Guangdong, 516000, China
-
Hunan Cancer Hospital
COMPLETEDChangsha, Hunan, 410013, China
-
Jiangsu Province Hospital
COMPLETEDNanjing, Jiangsu, 210029, China
-
Jilin Cancer Hospital
COMPLETEDChangchun, Jilin, 130021, China
-
Meizhou People Hospital
RECRUITINGMeizhou, Guangdong, 514031, China
-
Nanfang Hospital of Southern Medical University
COMPLETEDGuangzhou, Guangdong, 510515, China
-
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
COMPLETEDNanjing, Jiangsu, 210008, China
-
The Affiliated Hospital of Military Medical Sciences
COMPLETEDBeijing, Beijing Municipality, 100071, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
COMPLETEDHangzhou, Zhejiang, 310003, China
-
The First Peoples Hospital of Yibin
RECRUITINGYibin, Sichuan, 644000, China
-
The General Hospital of Shenyang Military
COMPLETEDShenyang, Liaoning, 110016, China
-
The Peoples Hospital of Hechi
RECRUITINGHechi, Guangxi, 547099, China
-
The Sixth Affiliated Hospital, Sun Yat Sen University
COMPLETEDGuangzhou, Guangdong, 510655, China
-
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
COMPLETEDWuhan, Hubei, 430030, China
-
Yidu Central Hospital of Weifang
RECRUITINGWeifang, Shandong, 262550, China
-
Zhejiang Cancer Hospital
COMPLETEDHangzhou, Zhejiang, 310022, China
-
Zhejiang University College of Medicine Second Affiliated Hospital
COMPLETEDHangzhou, Zhejiang, 310009, China